MedTrace Logo

Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

NCT00213278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-11-20

No results posted yet for this study

Summary

This study is examining whether Vinblastine is an effective drug to shrink low grade glioma brain tumors in children, and what the side effects are.

Conditions

Interventions

DRUG

vinblastine sulphate injection

Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.

Sponsors & Collaborators

  • Ontario Cancer Research Network

    collaborator NETWORK

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Eric Bouffet, MD · The Hospital for Sick Children, Toronto Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Day
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2011-09-30
Completion
2012-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00213278 on ClinicalTrials.gov